Numab raises $110m to develop cancer bispecific antibodiesSwitzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to Share XNumab raises $110m to develop cancer bispecific antibodieshttps://pharmaphorum.com/news/numab-raises-110m-to-develop-cancer-bispecific-antibodies/
